rubitecan has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burris, HA; Gerstein, H; Harris, J; Mettinger, KL; Reynolds, R; Rivkin, S; Staddon, A; Wax, A | 1 |
| Chedid, S; Cristofanilli, M; Esteva, F; Frye, DK; Hortobagyi, G; Ibrahim, N; Mettinger, KL; Rivera, E; Valero, V | 1 |
2 trial(s) available for rubitecan and Disease Exacerbation
| Article | Year |
|---|---|
Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Disease Progression; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2005 |
Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Disease Progression; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Treatment Outcome | 2006 |